Publicité
Publicité

VTGN

VTGN logo

Vistagen Therapeutics, Inc. Common Stock

0.70
USD
Sponsorisé
-0.04
-4.81%
08 janv., 15:59 UTC -5
Fermé
exchange

Après-marché

0.71

+0.01
+0.86%

VTGN Rapports sur les bénéfices

Ratio de surprise positive

VTGN a dépassé 19 des 37 dernières estimations.

51%

Prochain rapport

Date du prochain rapport
11 févr. 2026
Estimate for Q3 26 (Revenue/ EPS)
$373.32K
/
-$0.48
Variation implicite de Q2 26 (Revenue/ EPS)
+44.70%
/
-11.11%
Variation implicite de Q3 25 (Revenue/ EPS)
+59.54%
/
+4.35%

Vistagen Therapeutics, Inc. Common Stock earnings per share and revenue

On 13 nov. 2025, VTGN reported earnings of -0.54 USD per share (EPS) for Q2 26, missing the estimate of -0.48 USD, resulting in a -11.23% surprise. Revenue reached 258.00 mille, compared to an expected 248.20 mille, with a 3.95% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analystes forecast an EPS of -0.48 USD, with revenue projected to reach 373.32 mille USD, implying an baisse of -11.11% EPS, and hausse of 44.70% in Revenue from the last quarter.
FAQ
For Q2 2026, Vistagen Therapeutics, Inc. Common Stock reported EPS of -$0.54, missing estimates by -11.23%, and revenue of $258.00K, 3.95% above expectations.
The stock price moved -- 0%, changed from $3.80 before the earnings release to $3.80 the day after.
The next earning report is scheduled for 11 févr. 2026.
Based on 7 analystes, Vistagen Therapeutics, Inc. Common Stock is expected to report EPS of -$0.48 and revenue of $373.32K for Q3 2026.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité